XENE
Xenon Pharmaceuticals Inc.
NasdaqGMUSDEQUITY
Healthcare
DELAYED
Last price
60.01
▲ 0.28 (0.47%)
MARKET · —
Price
Chart style
Interval
Intraday intervals only cover recent history. The site picks the finest interval the range allows.
Overlays
Session levels
Lower pane
Tool
Drag pan · Pinch zoom · Hold crosshair · pick a tool then drag to draw
Open
59.75
Prev close
59.73
Day high
61.57
Day low
59.73
Volume
792.93K
Market cap
$5.88B
P/E (TTM)
—
52W range
35.60 – 72.66
Day trading desk
Gap from prior close
+0.03%
Prior close 59.73
VWAP
60.94
-1.52% from price
Relative volume
0.60×
Normal
Session range
12.39%
56.50 – 63.50
Position in range
50%
Mid range
ATR (14D)
2.17
3.62% of price
Prior day high
62.51
PDH
Prior day low
59.27
PDL
Bid / ask spread
—
Quote not published
Session volume
793.40K
Avg 1.32M
VWAP and the session figures are computed from the delayed intraday series on this page, so they lag the live tape and will not match a broker's real-time VWAP exactly. Turn on Prior day H/L/C, Opening range and Volume profile in the chart's Studies menu to see these levels drawn on price.
Trailing performance
Returnvs SPY
1W
-2.53%
-1.2%
1M
-7.11%
-10.8%
3M
+12.29%
+9.2%
6M
+43.90%
+32.8%
YTD
+35.59%
+23.3%
1Y
+61.45%
+41.5%
3Y
+66.63%
-7.5%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Unusual options activity
Nothing crossed the thresholds in the expiries we scanned.
That is the normal state — most contracts trade well inside their existing open interest.
That is the normal state — most contracts trade well inside their existing open interest.
Contracts trading at or above their open interest, ranked by notional and where the print landed.
Free account
5 more panels on XENE open with an account.
Options chains and analytics, valuation ratios, insider filings, analyst targets and ownership. No card, no trial, nothing to cancel.
Insider net activity
Net shares
+37.80K
Net buying
Buy transactions
14
347.01K shares
Sell transactions
9
309.22K shares
Net transactions
+23
Buys less sells
Sell : buy shares
0.9 : 1
Mixed
Insider-held shares
110.40K
Total on file
Insider transactions
| Date | Insider | Action | Shares | Value | Held |
|---|---|---|---|---|---|
| Aug 11, 26 | GANNON STEVEN Director |
SELL | 10.00K | $640.55K | Direct |
| Jun 5, 26 | PATOU GARY Director |
SELL | 1.32K | $70.25K | Direct |
| Jun 5, 26 | CANNON GILLIAN Director |
SELL | 1.19K | $63.24K | Direct |
| Jun 1, 26 | PATOU GARY Director |
— | 2.65K | — | Direct |
| Jun 1, 26 | SVORONOS DAWN A Director |
— | 2.65K | — | Direct |
| Jun 1, 26 | GANNON STEVEN Director |
— | 2.65K | — | Direct |
| Jun 1, 26 | MACHADO PATRICK Director |
— | 2.65K | — | Direct |
| Jun 1, 26 | GOVER JUSTIN DAVID Director |
— | 2.65K | — | Direct |
| Jun 1, 26 | GAROFALO ELIZABETH AMY M.D. Director |
— | 2.65K | — | Direct |
| Jun 1, 26 | CANNON GILLIAN Director |
— | 2.65K | — | Direct |
| May 12, 26 | GANNON STEVEN Director |
CONVERSION | 3.50K | $25.83K | Direct |
| Mar 13, 26 | MORTIMER IAN C Chief Executive Officer |
SELL | 7.31K | $403.58K | Direct |
| Mar 13, 26 | DIFABIO ANDREA Officer |
SELL | 1.34K | $74.11K | Direct |
| Mar 13, 26 | KENNEY CHRISTOPHER JOHN Officer |
SELL | 1.41K | $77.87K | Direct |
What this is, and what it is not
These are SEC Form 4 filings — officers, directors and 10% owners reporting their own trades in the company's stock. Filing is due within two business days of the transaction, so this lags reality by days, and the provider adds its own lag on top.
A sale is not automatically bearish. Executives sell on scheduled 10b5-1 plans, to cover tax on vesting equity, and to diversify. Purchases with cash are generally the more informative signal, and they are far rarer.
This does not include congressional or senate trading. That comes from STOCK Act disclosures filed with the Senate eFD system and the House Clerk, which this data source does not carry.
Officer and director trades in their own stock, straight from Form 4 filings.
Insider holders
| Name | Relation | Shares held | Latest |
|---|---|---|---|
CANNON GILLIAN |
Director | 1.46K | Sale |
DIFABIO ANDREA |
Officer | 7.30K | Sale |
GANNON STEVEN |
Director | 1.87K | Sale |
GAROFALO ELIZABETH AMY M.D. |
Director | 2.65K | Conversion of Exercise of derivative security |
GOVER JUSTIN DAVID |
Director | 2.65K | Conversion of Exercise of derivative security |
KENNEY CHRISTOPHER JOHN |
Officer | 7.07K | Sale |
MACHADO PATRICK |
Director | 2.65K | Conversion of Exercise of derivative security |
MORTIMER IAN C |
Chief Executive Officer | 34.22K | Sale |
PATOU GARY |
Director | 29.80K | Sale |
SVORONOS DAWN A |
Director | 26.23K | Conversion of Exercise of derivative security |
Fundamentals
Market cap$5.88B
Enterprise value$4.96B
Revenue (TTM)$0
Gross profit$-352.48M
EBITDA$-439.19M
Net income$-409.20M
EPS (TTM)$-4.74
Free cash flow$-203.55M
Total cash$930.69M
Total debt$6.42M
Book value / share$12.84
Shares outstanding96.84M
Float90.95M
Short % of float5.58%
Dividend yield—
Beta (5Y)0.63
Valuation & profitability ratios
Trailing P/E—
Forward P/E-12.49
PEG ratio—
Price / sales—
Price / book4.73
EV / revenue—
EV / EBITDA-11.30
Gross margin0.00%
Operating margin0.00%
Profit margin0.00%
Return on equity-43.62%
Return on assets-28.02%
Debt / equity0.52
Current ratio21.02
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Total revenue | $7.50M | $0 | $0 | $9.43M | — |
| Operating revenue | $7.50M | $0 | $0 | $9.43M | — |
| Research & development | $300.94M | $210.39M | $167.51M | $105.77M | +43.0% |
| Selling, general & admin | $79.63M | $68.90M | $46.54M | $32.81M | +15.6% |
| Total operating expense | $380.57M | $279.30M | $214.05M | $138.58M | +36.3% |
| Operating income | -$373.07M | -$279.30M | -$214.05M | -$129.14M | -33.6% |
| Net interest income | $26.83M | $41.94M | $27.62M | $8.71M | -36.0% |
| Pre-tax income | -$344.89M | -$238.42M | -$182.69M | -$125.25M | -44.7% |
| Tax provision | $1.02M | -$4.09M | -$292.00K | $118.00K | +124.8% |
| Net income | -$345.91M | -$234.33M | -$182.39M | -$125.37M | -47.6% |
| Net income to common | -$345.91M | -$234.33M | -$182.39M | -$124.94M | -47.6% |
| Basic EPS | -4.36 | -3.01 | -2.73 | -2.06 | -44.9% |
| Diluted EPS | -4.36 | -3.01 | -2.73 | -2.06 | -44.9% |
| EBIT | -$373.07M | -$279.30M | -$214.05M | -$129.14M | -33.6% |
| EBITDA | -$370.53M | -$276.74M | -$211.99M | -$127.74M | -33.9% |
| Basic shares | 79.25M | 77.89M | 66.89M | 60.54M | +1.7% |
| Diluted shares | 79.25M | 77.89M | 66.89M | 60.54M | +1.7% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Cash & equivalents | $199.16M | $142.71M | $148.64M | $57.24M | +39.6% |
| Cash & short-term investments | $548.89M | $626.90M | $638.08M | $592.09M | -12.4% |
| Accounts receivable | $1.37M | $1.47M | $874.00K | $986.00K | -6.7% |
| Total current assets | $560.65M | $635.26M | $644.96M | $600.30M | -11.7% |
| Property, plant & equipment | $15.35M | $18.22M | $18.85M | $16.91M | -15.8% |
| Total assets | $633.16M | $798.14M | $964.80M | $754.15M | -20.7% |
| Total current liabilities | $41.79M | $35.59M | $27.27M | $22.70M | +17.4% |
| Total debt | $7.94M | $9.02M | $10.90M | $10.44M | -11.9% |
| Total liabilities | $51.40M | $43.24M | $36.88M | $32.65M | +18.9% |
| Retained earnings | -$1.25B | -$899.47M | -$665.14M | -$482.75M | -38.5% |
| Shareholder equity | $581.76M | $754.90M | $927.92M | $721.50M | -22.9% |
| Working capital | $518.86M | $599.67M | $617.69M | $577.60M | -13.5% |
| Net tangible assets | $581.76M | $754.90M | $927.92M | $721.50M | -22.9% |
| Shares issued | 80.01M | 76.42M | 75.37M | 62.59M | +4.7% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Net income | -$345.91M | -$234.33M | -$182.39M | -$125.37M | -47.6% |
| Depreciation & amortisation | $2.54M | $2.56M | $2.06M | $1.41M | -0.7% |
| Stock-based compensation | $53.71M | $50.72M | $32.37M | $20.38M | +5.9% |
| Change in working capital | $4.36M | $5.71M | $5.90M | -$1.28M | -23.7% |
| Operating cash flow | -$279.12M | -$181.39M | -$151.11M | -$101.03M | -53.9% |
| Capital expenditure | -$799.00K | -$3.08M | -$5.62M | -$2.89M | +74.0% |
| Investing cash flow | $218.00M | $165.00M | -$111.39M | -$293.40M | +32.1% |
| Financing cash flow | $117.11M | $12.13M | $353.52M | $278.47M | +865.5% |
| Free cash flow | -$279.92M | -$184.46M | -$156.73M | -$103.92M | -51.7% |
| End cash position | $199.16M | $142.71M | $148.64M | $57.24M | +39.6% |
| Line item | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | YoY |
|---|---|---|---|---|---|---|
| Total revenue | $0 | $0 | $0 | $0 | $7.50M | — |
| Operating revenue | $0 | $0 | $0 | $0 | $7.50M | — |
| Research & development | $88.51M | $87.70M | $77.05M | $74.98M | $61.20M | +0.9% |
| Selling, general & admin | $23.82M | $22.07M | $19.28M | $19.24M | $19.04M | +7.9% |
| Total operating expense | $112.33M | $109.77M | $96.34M | $94.23M | $80.24M | +2.3% |
| Operating income | -$112.33M | -$109.77M | -$96.34M | -$94.23M | -$72.74M | -2.3% |
| Net interest income | $6.91M | $5.34M | $6.21M | $7.20M | $8.08M | +29.3% |
| Pre-tax income | -$104.87M | -$104.72M | -$90.22M | -$85.33M | -$64.62M | -0.1% |
| Tax provision | -$2.57M | $538.00K | $677.00K | -$626.00K | $427.00K | -577.9% |
| Net income | -$102.30M | -$105.26M | -$90.90M | -$84.71M | -$65.05M | +2.8% |
| Net income to common | -$102.30M | -$105.26M | -$90.90M | -$84.71M | -$65.05M | +2.8% |
| Basic EPS | -1.17 | -1.31 | -1.15 | -1.07 | -0.83 | +10.7% |
| Diluted EPS | -1.17 | -1.31 | -1.15 | -1.07 | -0.83 | +10.7% |
| EBIT | -$112.33M | -$109.77M | -$96.34M | -$94.23M | -$72.74M | -2.3% |
| EBITDA | -$111.74M | -$109.16M | -$95.69M | -$93.60M | -$72.08M | -2.4% |
| Basic shares | 87.35M | 80.13M | 79.25M | 78.95M | 78.69M | +9.0% |
| Diluted shares | 87.35M | 80.13M | 79.25M | 78.95M | 78.69M | +9.0% |
| Line item | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | YoY |
|---|---|---|---|---|---|---|
| Cash & equivalents | $545.87M | $199.16M | $104.51M | $135.38M | $116.66M | +174.1% |
| Cash & short-term investments | $1.09B | $548.89M | $462.27M | $487.55M | $549.63M | +99.4% |
| Accounts receivable | $1.17M | $1.37M | $812.00K | $1.10M | $8.65M | -15.0% |
| Total current assets | $1.11B | $560.65M | $480.14M | $500.25M | $565.54M | +97.4% |
| Property, plant & equipment | $14.58M | $15.35M | $15.85M | $16.50M | $17.31M | -5.0% |
| Total assets | $1.39B | $633.16M | $607.84M | $674.28M | $743.28M | +119.0% |
| Total current liabilities | $39.81M | $41.79M | $38.34M | $33.05M | $32.03M | -4.7% |
| Total debt | $7.49M | $7.94M | $8.33M | $8.71M | $8.68M | -5.7% |
| Total liabilities | $48.99M | $51.40M | $48.33M | $40.30M | $39.32M | -4.7% |
| Retained earnings | -$1.35B | -$1.25B | -$1.14B | -$1.05B | -$964.52M | -8.2% |
| Shareholder equity | $1.34B | $581.76M | $559.51M | $633.98M | $703.96M | +130.0% |
| Working capital | $1.07B | $518.86M | $441.80M | $467.20M | $533.51M | +105.6% |
| Net tangible assets | $1.34B | $581.76M | $559.51M | $633.98M | $703.96M | +130.0% |
| Shares issued | 96.62M | 80.01M | 77.12M | 76.73M | 76.59M | +20.8% |
| Line item | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | YoY |
|---|---|---|---|---|---|---|
| Net income | -$102.30M | -$105.26M | -$90.90M | -$84.71M | -$65.05M | +2.8% |
| Depreciation & amortisation | $587.00K | $611.00K | $641.00K | $632.00K | $659.00K | -3.9% |
| Stock-based compensation | $16.89M | $14.12M | $13.71M | $13.71M | $12.17M | +19.7% |
| Change in working capital | -$3.38M | $8.97M | $4.96M | $2.62M | -$12.19M | -137.7% |
| Operating cash flow | -$88.90M | -$81.48M | -$71.75M | -$64.23M | -$61.65M | -9.1% |
| Capital expenditure | -$133.00K | -$318.00K | -$281.00K | -$157.00K | -$43.00K | +58.2% |
| Investing cash flow | -$407.28M | $62.70M | $38.53M | $82.26M | $34.51M | -749.6% |
| Financing cash flow | $843.01M | $113.54M | $2.36M | $65.00K | $1.15M | +642.5% |
| Free cash flow | -$89.03M | -$81.80M | -$72.03M | -$64.39M | -$61.70M | -8.8% |
| End cash position | $545.87M | $199.16M | $104.51M | $135.38M | $116.66M | +174.1% |
Options analytics
Put / call volume
158.38
Put-heavy session
Put / call open interest
0.21
Positioning, not flow
Max pain
57.50
-5.4% from spot
ATM implied vol
53.5%
Nearest strike to spot
Skew (10% OTM)
-4.3%
Calls bid over puts
Call volume
16
Contracts, this expiry
Put volume
2.53K
Contracts, this expiry
Heaviest call OI
62.50
57 contracts
Heaviest put OI
55.00
6 contracts
Max pain is the strike at which the largest dollar value of open contracts expires worthless. It describes current positioning; it is not a forecast and it moves as open interest changes.
Put/call ratios, max pain, implied volatility skew and where open interest is concentrated.
Earnings
Reported vs expected · EPS
| Quarter | Est. | Actual | Surprise |
|---|---|---|---|
| Jun 2026 | -1.16 | -1.11 | +4.4% |
| Mar 2026 | -1.20 | -1.17 | +2.3% |
| Dec 2025 | -1.21 | -1.31 | -8.7% |
| Sep 2025 | -1.16 | -1.15 | +1.2% |
Forward consensus
| Period | EPS | Analysts | Revenue | Growth |
|---|---|---|---|---|
| Current quarter | -1.16 | 14 | $0 | 0.0% |
| Next quarter | -1.18 | 14 | $788.38K | 0.0% |
| Current year | -4.63 | 14 | $1.18M | -84.2% |
| Next year | -4.87 | 16 | $28.57M | +2,314.8% |
Analyst targets & ownership
Mean target$81.30
High target$100.00
Low target$69.00
Implied upside35.47%
Analyst count19
ConsensusSTRONG BUY
Strong buy / Buy3 / 17
Hold0
Sell / Strong sell0 / 0
Held by insiders0.11%
Held by institutions107.62%
Institutions holding437
Price targets, consensus spread, insider and institutional ownership.
Moving averages & technicals
SMA 10
62.77
-4.39% from price
SMA 20
63.34
-4.06% from price
SMA 50
62.13
-2.18% from price
SMA 100
58.90
+1.88% from price
SMA 200
51.72
+17.49% from price
EMA 12
62.53
-4.03% from price
EMA 26
63.00
-4.75% from price
EMA 50
61.86
-2.99% from price
RSI (14)
42.4
Neutral
MACD (12,26,9)
-0.47
Hist -0.55
ATR (14)
2.17
3.57% of price
Realised vol 30D
28.8%
Annualised
Bollinger upper
66.23
20, 2σ
Bollinger lower
60.45
20, 2σ
50 / 200 cross
Golden
62.13 vs 51.72
Trend bias
Above 200
+17.49%
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Risk profile
Beta vs SPY
0.83
Less volatile than market
Correlation to SPY
0.18
Largely independent
Realised vol 30D
28.8%
Annualised
Market vol 1Y
12.9%
SPY, annualised
Max drawdown 1Y
-18.4%
Peak to trough
Max drawdown 5Y
-43.6%
Peak to trough
ATR 14
2.17
3.57% of price
Beta (reported)
0.63
5Y monthly, from filing
Short interest
Shares short
5.38M
Prior 6.26M
Change vs prior
-14.0%
Shorts covering
% of float
5.58%
Normal
% of shares out
5.57%
Against total outstanding
Days to cover
4.4
Liquid
Float
90.95M
Freely tradeable shares
Exchanges publish short interest twice a month with a settlement lag, so this is roughly two weeks behind. Days to cover divides shares short by average daily volume — it estimates how long covering would take, not whether it will happen.
Rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Aug 7, 26 | RBC Capital | MAINTAINED | Outperform | Outperform |
| May 27, 26 | JP Morgan | MAINTAINED | Overweight | Overweight |
| May 12, 26 | JP Morgan | MAINTAINED | Overweight | Overweight |
| May 8, 26 | RBC Capital | MAINTAINED | Outperform | Outperform |
| May 8, 26 | Needham | MAINTAINED | Buy | Buy |
| Mar 16, 26 | Wedbush | MAINTAINED | Outperform | Outperform |
| Mar 10, 26 | Wells Fargo | MAINTAINED | Overweight | Overweight |
| Mar 10, 26 | Wedbush | MAINTAINED | Outperform | Outperform |
| Mar 10, 26 | Deutsche Bank | MAINTAINED | Buy | Buy |
| Mar 10, 26 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Mar 9, 26 | Needham | MAINTAINED | Buy | Buy |
| Mar 9, 26 | Baird | MAINTAINED | Outperform | Outperform |
SEC filings
Periodic Financial Reports
10-Q · 2026-08-06
Offering Registrations
S-8 · 2026-06-03
Periodic Financial Reports
10-Q · 2026-05-07
Proxy Statements
DEF 14A · 2026-04-22
Corporate Changes & Voting Matters
8-K · 2026-04-13
Corporate Changes & Voting Matters
8-K · 2026-03-13
Corporate Changes & Voting Matters
8-K · 2026-02-26
Corporate Changes & Voting Matters
8-K · 2025-12-01
Headlines
Xenon Pharmaceuticals (XENE) Q2 2026 Earnings Call Transcript
Motley Fool · 10d ago
Xenon Pharmaceuticals Insider Sold Shares Worth $640,550, According to a Recent SEC Filing
MT Newswires · 10d ago
Major Depressive Disorder Market is Predicted to Grow During the Forecast Period (2026-2036) as Novel Antidepressants are Expected to Enter the Market | DelveInsight
PR Newswire · 13d ago
Xenon Pharmaceuticals Q2 Earnings Call Highlights
MarketBeat · 16d ago
Xenon Pharmaceuticals' Azetukalner NDA Filing Remains on Track After FDA Meeting, RBC Says
MT Newswires · 16d ago
XENE's Q2 Loss Narrower Than Expected, Sales Nil, Pipeline in Focus
Zacks · 16d ago
Wedbush Adjusts PTon Xenon Pharmaceuticals to $71 From $63, Maintains Outperform Rating
MT Newswires · 16d ago
Xenon Pharmaceuticals Inc (XENE) (Q2 2026) Earnings Call Highlights: Advancing Azetukalner ...
GuruFocus.com · 17d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.